RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Arcadia Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Crude Petroleum & Natural Gas companies for comparison
Valuation
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Market Cap | $349.34K | $958.03M |
| Enterprise Value | -$3.83M | $1.17B |
| PS Ratio | 0.07 | 1.87 |
Enterprise value
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| EV / Sales | -0.81 | 2.29 |
Income (trailing twelve months)
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Revenue | $4.75M | $893.82M |
| Gross Profit | $1.64M | $263.25M |
| Operating Income | -$3.80M | $37.73M |
| Net Income | -$11.13M | $2.91M |
| EBITDA | -$3.80M | $104.88M |
| EPS (Diluted) | -$4.55 | $0.23 |
Margins
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Gross Margin | 34.6% | 24.0% |
| Operating Margin | -80.1% | 9.34% |
| Profit Margin | -234.5% | 2.45% |
| EBITDA Margin | -80.1% | 19.8% |
Returns
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Return on Assets (ROA) | -162.7% | 0.52% |
| Return on Capital Employed (ROCE) | -89.5% | 4.89% |
Growth
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -12.2% | 5.39% |
| Revenue Growth (3Y CAGR) | -13.2% | 0.47% |
| Revenue Growth (5Y CAGR) | -9.57% | 15.5% |
Balance sheet
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.18M | $37.22M |
| Net Cash (Debt) | $4.18M | -$12.28M |
| Net Cash Per Share | $1.73 | -$0.15 |
| Working Capital | $4.09M | $3.14M |
Financial position
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Current Ratio | 3.49 | 1.18 |
| Quick Ratio | 2.54 | 0.73 |
Cash flow (trailing twelve months)
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.50M | $192.72M |
Efficiency
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.69 | 0.39 |
| Inventory Turnover | 2.57 | 10.85 |
| Revenue Per Employee | $593.25K | $1.59M |
| Profits Per Employee | -$1.39M | $6.39K |
| Employee Count | 8 | 370 |
Dividends and yields
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -3186.3% | 0.55% |
Shares
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 2,409,210 | 105,192,000 |
| Shares Change (YoY) | 43.2% | 1.06% |
| Shares Change (QoQ) | 6.07% | 0.02% |
| Float | 2,375,190 | 76,585,800 |
| Shares Held by Insiders | 1.41% | 9.89% |
| Shares Held by Institutions | 8.78% | 69.2% |
Scores
| Measure | Arcadia Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -69.79 | 1.62 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Arcadia Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.